Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
Status:
Not yet recruiting
Trial end date:
2021-11-19
Target enrollment:
Participant gender:
Summary
This study consists of 2 parts: Part 1 and 2. The purpose of this study is to evaluate the
pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of
digoxin, metformin and rosuvastatin in Part-1 and sumatriptan in Part-2 of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany